2021 AGM

Dear Shareholder:

In normal circumstances, I would be sending this letter to you as an invitation to personally attend our 2021 annual shareholder meeting to be held on Monday, June 28, 2021 at our principal executive offices located at Unit 100 – 740 McCurdy Road, Kelowna, BC  V1X 2P7. 

However, these are certainly not normal circumstances and in an effort to ensure the safety of our shareholders and management, we are instead limiting in person attendance to our executives and encouraging you to vote by proxy or by attending our shareholder meeting by way of joining our event conferencing session via the following number:   for Toronto residents (416) 764-8658 or toll-free at 1-888-886-7786.  You will be provided with an opportunity to vote on the proposals contained in the attached proxy circular at the event conferencing session.  The proxy materials are first being made available to our shareholders on or about May 14, 2021.

The meeting will begin promptly at 1:00 p.m. PST. 

In order to facilitate clear communications, all participants will be placed in lecture mode and will have their microphones muted.  We encourage you to email any questions that you may have regarding the proposals to the Company in advance of the meeting.  Please provide your questions to our Head of Legal, Vanessa Carle at vcarle@lexariabioscience.com as we will only be answering questions on proposals that are submitted in advance and a maximum of two (2) questions per proposal during the Meeting.  When we come to each proposal that requires a vote, we will have the moderator provide instructions on the process for asking questions for the purposes of discussion on the proposal.    Once the questions have been responded to, the moderator will provide instructions on the method of voting on the proposal.

In addition to the matters described in the Notice of Annual Meeting of Shareholders and the Proxy Statement, we will be conducting a question and answer session after the termination of the meeting (the “Q & A Session”).  The Q & A Session will entail the Chief Executive Officer answering questions that were submitted in advance of the Meeting; it should be noted that no new questions will be taken from attendees during the Q & A session.  In order to ensure that we are able to address as many general questions as possible, we encourage you to forward your questions in advance of the meeting by emailing our Head of Legal, Vanessa Carle at vcarle@lexariabioscience.com who will then ensure that they are answered at the end of the meeting. 

The members of the Board and management hope that you and your loved ones are staying healthy and safe.   


Christopher Bunka

Chief Executive Officer & Chairman

2021 Annual General Meeting Documents

Download 2021 Proxy Statement

Download Form of Proxy PDF

Download Form of Notice